Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro

Cellular and Molecular Neurobiology

Volumn 31, Issue 2, 2011, Pages 195-202

  Bologov, Anastasia ^a   Gafni, Mikhal ^a   Keren, Ora ^a   Sarne, Yosef ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cannabinoid; Cannabinoid receptors; N18TG2; Neuroprotective; Neurotoxic

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CASPASE 3; DEXANABINOL; DIMETHYL SULFOXIDE; LACTATE DEHYDROGENASE; TETRAHYDROCANNABINOL;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL COMMUNICATION; CELL FUNCTION; CELL GROWTH; CELL STRAIN HEK293; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE;

CANNABINOIDS; CASPASE 3; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, SERUM-FREE; CYCLOHEXANOLS; GLUCOSE; HEK293 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RECEPTOR, CANNABINOID, CB1; STRESS, PHYSIOLOGICAL;

EID: 79959715360     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-010-9604-y     Document Type: Article

References (43)

1. Abood ME, Rizvi G, Sallapudi N, McAllister SD (2001) Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 309:197-201 (Pubitemid 32763173)
2. Bash R, Rubovitch V, Gafni M, Sarne Y (2003) The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12:39-44 (Pubitemid 37490491)
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104 (Pubitemid 28337591)
4. Binyaminy B, Gafni M, Shapira M, Sarne Y (2008) Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists. Life Sci 82:831-839
5. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M, Barth F, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P (1997) A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272:22330-22339 (Pubitemid 27382869)
6. Caulfield MP, Brown DA (1992) Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 106:231-232
7. Chen C, Okayama H (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 7:2745-2752
8. Di Marzo V (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7:438-455
9. Downer EJ, Gowran A, Campbell VA (2007) A comparison of the apoptotic effect of Delta(9)-tetrahydrocannabinol in the neonatal and adult rat cerebral cortex. Brain Res 1175:39-47 (Pubitemid 47513013)
10. Galve-Roperh I, Aguado T, Palazuelos J, Guzman M (2008) Mechanisms of control of neuron survival by the endocannabinoid system. Curr Pharm Des 14:2279-2288
11. Georgieva T, Devanathan S, Stropova D, Park CK, Salamon Z, Tollin G, Hruby VJ, Roeske WR, Yamamura HI, Varga E (2008) Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur J Pharmacol 581:19-29
12. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, Lefkowitz RJ (2006) Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864 (Pubitemid 43855508)
13. Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327-5333
14. Glass M, Northup JK (1999) Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56:1362-1369
15. Goncharov I, Weiner L, Vogel Z (2005) Delta9-tetrahydrocannabinol increases C6 glioma cell death produced by oxidative stress. Neuroscience 134:567-574 (Pubitemid 41111784)
16. Guzman M, Sanchez C, Galve-Roperh I (2002) Cannabinoids and cell fate. Pharmacol Ther 95:175-184 (Pubitemid 35232135)
17. Hampson AJ, Grimaldi M, Axelrod J, Wink D (1998) Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95:8268-8273 (Pubitemid 28326102)
18. Howlett AC (1995) Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35:607-634
19. Howlett AC, Qualy JM, Khachatrian LL (1986) Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs. Mol Pharmacol 29:307-313 (Pubitemid 16137598)
20. Hudson BD, Hebert TE, Kelly ME (2010) Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor. Mol Pharmacol 77:1-9
21. Johnson EA, Oldfield S, Braksator E, Gonzalez-Cuello A, Couch D, Hall KJ, Mundell SJ, Bailey CP, Kelly E, Henderson G (2006) Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol 70:676-685 (Pubitemid 44092328)
22. Kellogg R, Mackie K, Straiker A (2009) Cannabinoid CB1 receptor-dependent long-term depression in autaptic excitatory neurons. J Neurophysiol 102:1160-1171
23. Kim SH, Won SJ, Mao XO, Jin K, Greenberg DA (2006) Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity. Mol Pharmacol 69:691-696 (Pubitemid 43363843)
24. Mackie K, Hille B (1992) Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89:3825-3829
25. Maneuf YP, Brotchie JM (1997) Paradoxical action of the cannabinoid WIN 55, 212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120:1397-1398 (Pubitemid 27192426)
26. Matas D, Juknat A, Pietr M, Klin Y, Vogel Z (2007) Anandamide protects from low serum-induced apoptosis via its degradation to ethanolamine. J Biol Chem 282:7885-7892 (Pubitemid 47093601)
27. Mechoulam R, Panikashvili D, Shohami E (2002) Cannabinoids and brain injury: therapeutic implications. Trends Mol Med 8:58-61 (Pubitemid 34094440)
28. Molina-Holgado F, Pinteaux E, Heenan L, Moore JD, Rothwell NJ, Gibson RM (2005) Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol Cell Neurosci 28:189-194 (Pubitemid 39656022)
29. Mukhopadhyay S, Howlett AC (2005) Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol Pharmacol 67:2016-2024 (Pubitemid 41007783)
30. Pan X, Ikeda SR, Lewis DL (1998) SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 54:1064-1072 (Pubitemid 29002050)
31. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180
32. Pertwee RG (2005) Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 76:1307-1324
33. Roloff AM, Thayer SA (2009) Modulation of excitatory synaptic transmission by Delta 9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol 75:892-900
34. Rubovitch V, Gafni M, Sarne Y (2002) The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101:93-102 (Pubitemid 34465565)
35. Sanchez C, Galve-Roperh I, Canova C, Brachet P, Guzman M (1998) Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436:6-10 (Pubitemid 28454597)
36. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H (2005) Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65:1635-1641 (Pubitemid 40478586)
37. Sarne Y, Mechoulam R (2005) Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 4:677-684 (Pubitemid 41782629)
38. Seidman KJ, Barsuk JH, Johnson RF, Weyhenmeyer JA (1996) Differentiation of NG108-15 neuroblastoma cells by serum starvation or dimethyl sulfoxide results in marked differences in angiotensin II receptor subtype expression. J Neurochem 66:1011-1018 (Pubitemid 26065897)
39. Shapira M, Keren O, Gafni M, Sarne Y (2001) Divers pathways mediate delta-opioid receptor down regulation within the same cell. Brain Res Mol Brain Res 96:142-150 (Pubitemid 33145373)
40. Sinor AD, Irvin SM, Greenberg DA (2000) Endocannabinoids protect cerebral cortical neurons from in vitro ischemia in rats. Neurosci Lett 278:157-160 (Pubitemid 30009481)
41. Sugiura T, Kodaka T, Kondo S, Nakane S, Kondo H, Waku K, Ishima Y, Watanabe K, Yamamoto I (1997) Is the cannabinoid CB1 receptor a 2-arachidonoylglycerol receptor? Structural requirements for triggering a Ca2+ transient in NG108-15 cells. J Biochem (Tokyo) 122:890-895 (Pubitemid 27474963)
42. van der Stelt M, Di Marzo V (2005) Cannabinoid receptors and their role in neuroprotection. Neuromolecular Med 7:37-50
43. White R, Hiley CR (1998) The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125:689-696 (Pubitemid 28482608)